<DOC>
	<DOCNO>NCT01257009</DOCNO>
	<brief_summary>Hypertensive chronic kidney disease ( CKD ) patient often sympathetic hyperactivity appear contribute pathogenesis hypertension cardiovascular organ damage . Experimental study clinical study show statin therapy reduce central sympathetic activity . Blockade renin-angiotensin system ( RAS ) , standard treatment CKD , know lower sympathetic activity . The investigator hypothesize add statin 6 week RAS blockade would lower sympathetic activity hypertensive stage 2-4 CKD patient . Methods : In ten stable CKD patient chronic treatment renin-angiotenis blocker , blood pressure sympathetic activity ( quantified assessment muscle sympathetic nerve activity , MSNA ) assess baseline 6 week atorvastatin 20mg/day add . Ten CKD patient serve time control study twice interval 6 week without change medication , quantify within subject reproducibility .</brief_summary>
	<brief_title>Atorvastatin Sympathetic Activity Chronic Kidney Disease</brief_title>
	<detailed_description>see</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>stable chronic kidney disease Hypertension renal replacement therapy pregnancy diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>sympathetic activity</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>atorvastatin</keyword>
	<keyword>lipitor</keyword>
</DOC>